Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatment using Fin, Minoxidil and RU58841 with discussion about potential side effects and the power of nocebo effect.

A user switched from finasteride to Avodart (dutasteride) due to the ineffectiveness and poor quality of finasteride in their country. They advise others in similar situations to seek original brands.

Alternating between finasteride and dutasteride is being considered due to cost concerns. The user is worried about losing progress if switching entirely to dutasteride.

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

The user experienced positive scalp results with Dutasteride but noticed beard thinning, prompting a switch back to Finasteride. They plan to monitor the situation and may consider combining treatments in the future.

Considering a switch from finasteride to dutasteride for hair loss treatment, and the use of minoxidil as a last resort due to its effects on hair texture.

A user humorously discusses wanting to transplant all their hair into one dense circle on their scalp, leaving the rest of their head bald. Replies include a joke about performing the procedure and a story about someone using their hair to fight crime.

The user is pausing finasteride for blood donation and is concerned about its effect on DHT levels. They plan to supplement with saw palmetto and pumpkin seed oil during the pause.

The user is considering switching their hair loss routine from taking finasteride daily to a combination of finasteride six times a week and dutasteride once a week. They are seeking advice on this potential change.

The user is experiencing erectile dysfunction and emotional numbness, possibly due to using Dutasteride for hair loss, and is considering switching back to Finasteride. They are seeking advice on whether this change might resolve their symptoms.

Transitioning from finasteride to dutasteride for hair loss, with suggestions to either slowly transition or frontload dutasteride. The user is also using minoxidil, nizoral, needling, and LLLT.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.

Switching from finasteride to dutasteride as a treatment for hair loss, and discussing possible side effects or results of the switch.

Curved hair transplantation requires specialized tools and techniques to avoid damaging hair follicles, with modified FUE being the preferred method. Proper extraction and implantation angles are crucial to prevent complications like keloids and sterile folliculitis.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A user's experience taking finasteride, which resulted in them having an unexpected emotional reaction, and the replies to this post focus on the humorous aspects of cautionary tales about hair loss treatments.

A user has been on finasteride for over 1.5 years but is still losing hair, so they're switching to dutasteride and taking both for 3 months before stopping finasteride. They're concerned about potential hair shedding during the switch even when done correctly.

Switching from finasteride to dutasteride can cause significant hair shedding if done abruptly. It's recommended to overlap both treatments and gradually taper off finasteride to minimize shedding.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Finasteride can cause pelvic or urethral discomfort for some users. Reducing the dose to 0.25 mg on Mondays, Wednesdays, and Fridays is being considered as a potential solution.

The user has been taking finasteride for nearly 5 years and is now adding dutasteride to their regimen to maintain hair loss prevention. They seek advice on transitioning from finasteride to dutasteride.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

You cannot donate blood if you are taking finasteride or dutasteride due to potential risks to pregnant women. Finasteride has a shorter wait time to donate blood compared to dutasteride, and both oral and topical forms can disqualify you from donating.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.